CoChat
Sign Up
Cited by 28Parasitic Diseases Research and TreatmentParasites and Host InteractionsResearch on Leishmaniasis Studies

The DOI matches its Crossref record.

Comparison of Repeated Doses of Ivermectin Versus Ivermectin Plus Albendazole for the Treatment of Onchocerciasis: A Randomized, Open-label, Clinical Trial

Open access
Batsa Debrah, Linda, Klarmann-Schulz, Ute, Osei-Mensah, Jubin, Dubben, Bettina, Fischer, Kerstin, Mubarik, Yusif, Ayisi-Boateng, Nana Kwame, Ricchiuto, Arcangelo, Fimmers, Rolf, Konadu, Peter, Nadal, Jennifer, Gruetzmacher, Barbara, Weil, Gary, Kazura, James W, King, Christopher L, Debrah, Alexander Y, Hoerauf, Achim·2020·Clinical Infectious Diseases
DOI 10.1093/cid/ciz889PMC PMC7428389
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Improved treatment for onchocerciasis is needed to accelerate onchocerciasis elimination in Africa. Aiming to better exploit registered drugs, this study was undertaken to determine whether annual or semiannual treatment with ivermectin (IVM; 200 µg/kg) plus albendazole (ALB; 800 mg single dose) is superior to IVM alone. Methods: This trial was performed in Ghana and included 272 participants with microfilariae (MF), who were randomly assigned to 4 treatment arms: (1) IVM annually at 0, 12, and 24 months; (2) IVM semiannually at 0, 6, 12, 18, and 24 months; (3) IVM+ALB annually; or (4) IVM+ALB semiannually. Microfiladermia was determined pretreatment and at 6, 18, and 36 months. The primary outcome was the proportion of fertile and viable female worms in onchocercomata excised at 36 months. Results: Posttreatment nodule histology showed that 15/135 (11.1%), 22/155 (14.2%), 35/154 (22.7%), and 20/125 (16.0%) living female worms had normal embryogenesis in the IVM annual, IVM semiannual, IVM+ALB annual, and IVM+ALB semiannual groups, respectively (P = .1229). Proportions of dead worms also did not differ between the 4 groups (P = .9198). Proportions of patients without MF at 36 months (1 year after the last treatment) were 35/56 (63%) after annual IVM, 42/59 (71%) after semiannual IVM, 39/64 (61%) after annual IVM+ALB, and 43/53 (81%) after semiannual IVM+ALB. Conclusions: The combination treatment of IVM plus ALB was no better than IVM alone for sterilizing, killing adult worms, or achieving sustained MF clearance. However, semiannual treatment was superior to annual treatment for achieving sustained clearance of Onchocerca volvulus MF from the skin (P = .024). Clinical Trials Registration: ISRCTN50035143

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciz889

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Repeated use (annually or semiannually) of albendazole (800 mg single dose) with ivermectin (200 μg/kg single dose) for 2 years showed no better results than ivermectin alone for sterilizing and killing adult worms or achieving sustained microfilarial clearance in onchocerciasis.

    “Repeated use (annually or semiannually) of albendazole (800 mg single dose) with ivermectin (200 μg/kg single dose) for 2 years also showed no better results than ivermectin alone for sterilizing and killing adult worms or achieving sustained microfilarial clearance [215]”

    From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [215]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 30

  1. Simonsen, 2014, The filariases. Book: Manson’s tropical infectious diseases, 737, 10.1016/B978-0-7020-5101-2.00055-8 · DOI
  2. Basáñez, 2006, River blindness: a success story under threat?, PLOS Med, 3, e371, 10.1371/journal.pmed.0030371 · DOI
  3. Hopkins, 2016, Neglected tropical diseases in Africa: a new paradigm, Int Health, 8, i28, 10.1093/inthealth/ihv077 · DOI
  4. Basáñez, 2008, Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis, Lancet Infect Dis, 8, 310, 10.1016/S1473-3099(08)70099-9 · DOI
  5. Walker, 2017, Modelling the elimination of river blindness using long-term epidemiological and programmatic data from Mali and Senegal, Epidemics, 18, 4, 10.1016/j.epidem.2017.02.005 · DOI
  6. World Health Organization, 2015, Report of the consultative meetings on strategic options and alternative treatment strategies for accelerating onchocerciasis elimination in Africa
  7. Kim, 2015, Financial and economic costs of the elimination and eradication of onchocerciasis (river blindness) in Africa, PLOS Negl Trop Dis, 9, e0004056, 10.1371/journal.pntd.0004056 · DOI
  8. Awadzi, 2014, A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection, PLOS Negl Trop Dis, 8, e2953, 10.1371/journal.pntd.0002953 · DOI
  9. Turner, 2015, The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data, Parasit Vectors, 8, 167, 10.1186/s13071-015-0779-4 · DOI
  10. Opoku, 2018, Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial, Lancet, 392, 1207, 10.1016/S0140-6736(17)32844-1 · DOI
  11. Awadzi, 1991, The chemotherapy of onchocerciasis. XV. Studies with albendazole, Trop Med Parasitol, 42, 356
  12. Zahner, 1993, Experimental chemotherapy of filariasis: comparative evaluation of the efficacy of filaricidal compounds in Mastomys coucha infected with Litomosoides carinii, Acanthocheilonema viteae, Brugia malayi and B. pahangi, Acta Trop, 52, 221, 10.1016/0001-706X(93)90010-9 · DOI · Paper page
  13. Hoerauf, 2008, Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study, Med Microbiol Immunol, 197, 295, 10.1007/s00430-007-0062-1 · DOI
  14. Mand, 2005, Frequent detection of worm movements in onchocercal nodules by ultrasonography, Filaria J, 4, 1, 10.1186/1475-2883-4-1 · DOI
  15. Specht, 2009, Criteria for the differentiation between young and old Onchocerca volvulus filariae, Parasitol Res, 105, 1531, 10.1007/s00436-009-1588-5 · DOI
  16. Specht, 2009, Newly acquired Onchocerca volvulus filariae after doxycycline treatment, Parasitol Res, 106, 23, 10.1007/s00436-009-1624-5 · DOI
  17. Klarmann-Schulz, 2017, Comparison of doxycycline, minocycline, doxycycline plus albendazole and albendazole alone in their efficacy against onchocerciasis in a randomized, open-label, pilot trial, PLOS Negl Trop Dis, 11, e0005156, 10.1371/journal.pntd.0005156 · DOI · Paper page
  18. Harris, 2009, Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform, 42, 377, 10.1016/j.jbi.2008.08.010 · DOI · Paper page
  19. Awadzi, 2003, The co-administration of ivermectin and albendazole–safety, pharmacokinetics and efficacy against Onchocerca volvulus, Ann Trop Med Parasitol, 97, 165, 10.1179/000349803235001697 · DOI · Paper page
  20. Awadzi, 1995, The chemotherapy of onchocerciasis XX: ivermectin in combination with albendazole, Trop Med Parasitol, 46, 213
  21. Coffeng, 2014, Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment, PLOS One, 9, e115886, 10.1371/journal.pone.0115886 · DOI
  22. Hoerauf, 2003, Doxycycline in the treatment of human onchocerciasis: Kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms, Microbes Infect, 5, 261, 10.1016/S1286-4579(03)00026-1 · DOI
  23. Hoerauf, 2009, Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus, Parasitol Res, 104, 437, 10.1007/s00436-008-1217-8 · DOI
  24. Churcher, 2009, Identifying sub-optimal responses to ivermectin in the treatment of river blindness, Proc Natl Acad Sci USA, 106, 16716, 10.1073/pnas.0906176106 · DOI
  25. Katabarwa, 2014, Twice-yearly ivermectin for onchocerciasis: the time is now, Lancet Infect Dis, 14, 373, 10.1016/S1473-3099(14)70732-7 · DOI
  26. Turner, 2014, Reaching the London declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa, Clin Infect Dis, 59, 923, 10.1093/cid/ciu467 · DOI
  27. Burki, 2013, River blindness elimination in Columbia, Lancet Infect Dis, 13, 922, 10.1016/S1473-3099(13)70308-6 · DOI
  28. Ismail, 1998, Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis, Trans R Soc Trop Med Hyg, 92, 94, 10.1016/S0035-9203(98)90972-5 · DOI · Paper page
  29. Ismail, 2001, Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis, Trans R Soc Trop Med Hyg, 95, 332, 10.1016/S0035-9203(01)90257-3 · DOI
  30. Altman, 2000, Statistics with confidence, Confidence intervals and statistical guidelines

Cited by

Sorted by citations

Metadata

Authors
Batsa Debrah, L., Klarmann-Schulz, U., Osei-Mensah, J., Dubben, B., Fischer, K., Mubarik, Y., Ayisi-Boateng, N. K., Ricchiuto, A., Fimmers, R., Konadu, P., Nadal, J., Gruetzmacher, B., Weil, G., Kazura, J. W., King, C. L., Debrah, A. Y., & Hoerauf, A.
Affiliations
  • Kumasi Center for Collaborative Research, Kumasi, Ghana
  • Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany
  • University Hospital Bonn (DE)
  • Washington University in St. Louis (US)
  • University Hospital, , Kumasi, Ghana
  • Kwame Nkrumah University of Science and Technology (GH)
  • Case Western Reserve University (US)
ORCID
Venue
Clinical Infectious Diseases
Publisher
Oxford University Press (OUP)
Published
2019-09-19
Volume
71
Issue
4
Pages
933-943
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
DOI
10.1093/cid/ciz889
PMC
PMC7428389
OpenAlex
W2973861371
Cited by
28
References
0
Citations by year
2026: 5 · 2025: 2 · 2023: 9 · 2022: 6 · 2021: 4 · 2020: 2
FWCI
2.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Infectious Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • Greater South Information System
Funders
Bill and Melinda Gates Foundation (OPPGH5342)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Parasitic Diseases Research and Treatment
  • Life Sciences › Immunology and Microbiology › Parasitology › Parasites and Host Interactions
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Research on Leishmaniasis Studies
Keywords
onchocerciasis, ivermectin, albendazole, combination chemotherapy, microfilaremia, treatment frequency, onchocerciasis elimination, Onchocerca volvulus, Ghana, microfilariae, embryonic development, drug repurposing
MeSH terms
Animals, Female, Ghana, Humans, Ivermectin, Onchocerciasis, Albendazole, Onchocerca volvulus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review